Press monitoring
LivaNova PLC Receives Regulatory Approval in Japan for the Solo Smart Stentless Tissue Aortic Valve
29.2.2016 | Press monitoring
LONDON, Feb. 29, 2016 (GLOBE NEWSWIRE) -- LivaNova, PLC (NASDAQ:LIVN) (LSE:LIVN), a global medical technology company and a leader in the treatment of cardiovascular diseases, today announced that it has received approval from Japan's Pharmaceutical and Medical Devices Agency (PMDA) for its Solo Smart stentless tissue valve, the only valve...
Ordinary skin cells turned into brain tumor predators
29.2.2016 | Press monitoring
The 2006 discovery that mature skin cells can be converted into stem cells opened up exciting possibilities in regenerative medicine. Team from the University of North Carolina at Chapel Hill (UNC) has built on this technology to transform adult skin cells into cancer-killing stem cells that seek and destroy brain tumors. Glioblastomas are the...
Sobi and Biogen receive positive opinion from CHMP for Alprolix® (rFIXFc) for the treatment of haemophilia B
26.2.2016 | Press monitoring
Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO: SOBI) and Biogen (NASDAQ: BIIB) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending that marketing authorisation be granted for Alprolix® (rFIXFc), a recombinant factor IX Fc fusion protein therapy for the...
Artificial tail-less sperm is the best test-tube sex cell yet
26.2.2016 | Press monitoring
They can’t swim. But artificial mouse cells that resemble nearly mature sperm are the best test-tube sperm cells yet, meeting the elusive gold standard set in 2014. The cells resemble spermatids, the round cells that mature to form the familiar tailed sperm. Generated from embryonic stem cells, Jiahao Sha of Nanjing Medical University in China...
DNA \'Trojan horse\' smuggles drugs into resistant cancer cells
24.2.2016 | Press monitoring
Researchers at The Ohio State University are working on a new way to treat drug-resistant cancer that the ancient Greeks would approve of—only it's not a Trojan horse, but DNA that hides the invading force. In this case, the invading force is a common cancer drug. In laboratory tests, leukemia cells that had become resistant to the drug absorbed...
Neuroscientists reverse autism symptoms
22.2.2016 | Press monitoring
In a study of mice, MIT researchers have now shown that they can reverse some of those behavioral symptoms by turning the gene back on later in life, allowing the brain to properly rewire itself. Autism has diverse genetic causes, most of which are still unknown. About 1 percent of people with autism are missing a gene called Shank3, which is...
3D-printed ear, bone and muscle structures come to life after implantation in mice
19.2.2016 | Press monitoring
3D printed tissues and organs have shown real potential in addressing shortages of available donor tissue for people in need of transplants, but having them take root and survive after implantation has proven difficult to achieve. In a positive move for the technology, researchers have used with a newly-developed 3D printer to produce human-scale...
How will Nanomedicine revolutionize healthcare during the next 15 years?
17.2.2016 | Press monitoring
Paris, France, February 17, 2016 - European Technology Platform on Nanomedicine (ETPN ) announces the publication of the new Strategic Research and Innovation Agenda (SRIA) for Nanomedicine (available here: http://bit.ly/1mHpfGw ). This SRIA provides the ecosystem, including European, national and regional public authorities, a concrete framework...
Engineering researchers use laser to \"weld\" neurons
17.2.2016 | Press monitoring
A research team based in the Faculty of Engineering has developed a method of connecting neurons, using ultrashort laser pulses—a breakthrough technique that opens the door to new medical research and treatment opportunities. The team is the first ever to find a way to bond neurons and in doing so, has given researchers a powerful new tool....
Medigene secures additional viral vector production capacities for its clinical TCR studies
16.2.2016 | Press monitoring
Martinsried/Munich, 16 February 2016. Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T-cell immunotherapies for the treatment of cancer, has signed an agreement with the contract manufacturer EUFETS GmbH for the production and delivery of viral vectors. EUFETS is an...
